Clinipace Worldwide Expands into Asia with Acquisition of Choice Pharma
News Mar 15, 2014
Clinipace Worldwide has announced the closing of its merger with Choice Pharma, a Pan-Asian contract research organization.
Bringing these organizations together strengthens Clinipace Worldwide’s operational and therapeutic expertise in Asia, a region in high demand by Clinipace’s clients.
With the merger, the company extends its global footprint to include 20 operational offices in 15 countries, including new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia.
Chris Wang will continue in her role as Managing Director of Asian operations where she will manage day-to-day operating responsibilities reporting to CEO, Jeff Williams.
“In order to continue to address the changing industry landscape and the high demand by clients for operations in Asia, we began the process of determining the best path for investing in the growth of our company, which led us to Choice Pharma,” said Jeff Williams, CEO, Clinipace Worldwide. “With complementary operational strengths, a great reputation for quality and an experienced management team, the decision to combine the two companies was the best solution to continue to meet the long-term strategic goals of clients on both sides.”
Williams continues, “With staff located in over 30 countries, Clinipace is the only purpose-built CRO with deep therapeutic expertise and broad geographic capacity built on our proprietary technology-enabled service model that we call a digital CRO, or dCRO. This model delivers visibility and simplified study management through real-time performance metrics at a reduced cost to venture-based, mid-tier life science firms around the world.”
“A streamlined, efficient operational approach with real-time transparency that reduces cost and budget volatility is the future of clinical trials,” said Chris Wang, Managing Director, Choice Pharma. “Not only can our clients leverage Clinipace’s dCRO delivery model, but they now have access to a comprehensive and integrated clinical operations, data management, biostatistics, and regulatory consultancy outside of Asia.”
The combined company creates a formidable global clinical development service offering for the mid-market, along with a world-class product development, regulatory, and GxP/CMC/QA consultancy. Most importantly, Clinipace and Choice clients now have access to new markets for site activation and patient enrollment.
The 5th acquisition by Clinipace in recent years, the company is dedicated to building a new delivery model based on technological innovation, therapeutic expertise and global operations to support client needs.
Together, Clinipace Worldwide will now be home to over 640 global staff. The combined company has managed over 1,500 clinical research studies and 300+ completed regulatory and strategic development engagements.
Clinipace Worldwide will maintain its global headquarters in Research Triangle Park, NC with additional domestic operations in Irvine, CA, Overland Park, KS, and Boulder, CO; European operations in Zurich, Switzerland, Munich, Germany, and London, United Kingdom; Asian operations in Taipei, Taiwan, China offices in Beijing, Shanghai, Guangzhou, Seoul, South Korea, Hong Kong, Hanoi, Vietnam, Singapore, Kuala Lumpur, Malaysia; South American operations based in Sao Paulo, Brazil and Buenos Aires, Argentina ; Middle Eastern operations in Tel-Aviv, Israel and Indian operations in Trivandrum, India.
There are no layoffs or office closings planned; and the new combined organization will continue to hire throughout the year. Terms of the transaction will not be disclosed.